cancer epigenetics
Alterations in the epigenome are common in most cancers.
Changes in epigenetic signatures, including aberrant DNA methylation and histone deacetylation, are among the most prevalent modifications in cancer and lead to dramatic changes in gene expression patterns.
Because DNA methylation and histone deacetylation are reversible processes, they have become attractive as targets for cancer epigenetic therapy, both as single agents and as ’enhancing’ agents for other treatment strategies.
See also
epigenetic silencing (epimutations)
epigenetics
References
Epigenetics: Demethylation links cell fate and cancer. Swami M. Nat Rev Genet. 2010 Nov;11(11):749. PMID: #20921960#
Esteller M. Epigenetics in cancer. N Engl J Med. 2008 Mar 13;358(11):1148-59. PMID: #18337604#
Smith LT, Otterson GA, Plass C. Unraveling the epigenetic code of cancer for therapy. Trends Genet. 2007 Sep;23(9):449-56. PMID: #17681396#
Lim HN, van Oudenaarden A. A multistep epigenetic switch enables the stable inheritance of DNA methylation states. Nat Genet. 2007 Feb;39(2):269-75. PMID: #17220888#
Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I, Laird PW. Epigenetic stem cell signature in cancer. Nat Genet. 2007 Feb;39(2):157-8. PMID: #17200673#
Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet. 2006 Jan;7(1):21-33. PMID: #16369569#
Laird PW. Cancer epigenetics. Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R65-76. PMID: #15809275#
Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev. 2004 Oct 1;18(19):2315-35. PMID: #15466484# (Free)
Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003 Nov 20;349(21):2042-54. PMID: #14627790#
Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004 Feb;4(2):143-53. PMID: #14732866#
Plass C. Cancer epigenomics. Hum Mol Genet. 2002 Oct 1;11(20):2479-88. PMID: #12351584#